• Je něco špatně v tomto záznamu ?

Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma

MK. Ramirez-Fort, B. Meier-Schiesser, K. Lachance, SS. Mahase, CD. Church, MJ. Niaz, H. Liu, V. Navarro, A. Nikolopoulou, DV. Kazakov, E. Contassot, DP. Nguyen, J. Sach, L. Hadravsky, Y. Sheng, ST. Tagawa, X. Wu, CS. Lange, LE. French, PT....

. 2021 ; 1 (1) : . [pub] 20201128

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024658

Grantová podpora
K24 CA139052 NCI NIH HHS - United States
P01 CA225517 NCI NIH HHS - United States
P30 CA015704 NCI NIH HHS - United States

Backgrounds: Folate Hydrolase-1 (FOLH1; PSMA) is a type II transmembrane protein, luminally expressed by solid tumour neo-vasculature. Monoclonal antibody (mAb), J591, is a vehicle for mAb-based brachytherapy in FOLH1+ cancers. Brachytherapy is a form of radiotherapy that involves placing a radioactive material a short distance from the target tissue (e.g., on the skin or internally); brachytherapy is commonly accomplished with the use of catheters, needles, metal seeds and antibody or small peptide conjugates. Herein, FOLH1 expression in primary (p) and metastatic (m) Merkel cell carcinoma (MCC) is characterized to determine its targeting potential for J591-brachytherapy. Materials & Methods: Paraffin sections from pMCC and mMCC were evaluated by immunohistochemistry for FOLH1. Monte Carlo simulation was performed using the physical properties of conjugated radioisotope lutetium-177. Kaplan-Meier survival curves were calculated based on patient outcome data and FOLH1 expression. Results: Eighty-one MCC tumours were evaluated. 67% (54/81) of all cases, 77% (24/31) pMCC and 60% (30/50) mMCC tumours were FOLH1+. Monte Carlo simulation showed highly localized ionizing tracks of electrons emitted from the targeted neo-vessel. 42% (34/81) of patients with FOLH1+/- MCC had available survival data f or analysis. No significant differences in our limited data set were detected based on FOLH1 status (p = 0.4718; p = 0.6470), staining intensity score (p = 0.6966; p = 0.9841) or by grouping staining intensity scores (- and + vs. ++, +++, +++) (p = 0.8022; p = 0.8496) for MCC-specific survival or recurrence free survival, respectively. Conclusions: We report the first evidence of prevalent FOLH1 expression within MCC-associated neo-vessels, in 60-77% of patients in a large MCC cohort. Given this data, and the need for alternatives to immune therapies it is appropriate to explore the safety and efficacy o f FOLH1-targeted brachytherapy for MCC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024658
003      
CZ-PrNML
005      
20211013133831.0
007      
ta
008      
211006s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ski2.9 $2 doi
035    __
$a (PubMed)34541577
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ramirez-Fort, M K $u Department of Life Sciences, BioFort®, Guaynabo, Puerto Rico, USA $u Department of Urology, Weill Cornell Medicine, New York, New York, USA $u Department of Radiation Oncology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA
245    10
$a Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma / $c MK. Ramirez-Fort, B. Meier-Schiesser, K. Lachance, SS. Mahase, CD. Church, MJ. Niaz, H. Liu, V. Navarro, A. Nikolopoulou, DV. Kazakov, E. Contassot, DP. Nguyen, J. Sach, L. Hadravsky, Y. Sheng, ST. Tagawa, X. Wu, CS. Lange, LE. French, PT. Nghiem, NH. Bander
520    9_
$a Backgrounds: Folate Hydrolase-1 (FOLH1; PSMA) is a type II transmembrane protein, luminally expressed by solid tumour neo-vasculature. Monoclonal antibody (mAb), J591, is a vehicle for mAb-based brachytherapy in FOLH1+ cancers. Brachytherapy is a form of radiotherapy that involves placing a radioactive material a short distance from the target tissue (e.g., on the skin or internally); brachytherapy is commonly accomplished with the use of catheters, needles, metal seeds and antibody or small peptide conjugates. Herein, FOLH1 expression in primary (p) and metastatic (m) Merkel cell carcinoma (MCC) is characterized to determine its targeting potential for J591-brachytherapy. Materials & Methods: Paraffin sections from pMCC and mMCC were evaluated by immunohistochemistry for FOLH1. Monte Carlo simulation was performed using the physical properties of conjugated radioisotope lutetium-177. Kaplan-Meier survival curves were calculated based on patient outcome data and FOLH1 expression. Results: Eighty-one MCC tumours were evaluated. 67% (54/81) of all cases, 77% (24/31) pMCC and 60% (30/50) mMCC tumours were FOLH1+. Monte Carlo simulation showed highly localized ionizing tracks of electrons emitted from the targeted neo-vessel. 42% (34/81) of patients with FOLH1+/- MCC had available survival data f or analysis. No significant differences in our limited data set were detected based on FOLH1 status (p = 0.4718; p = 0.6470), staining intensity score (p = 0.6966; p = 0.9841) or by grouping staining intensity scores (- and + vs. ++, +++, +++) (p = 0.8022; p = 0.8496) for MCC-specific survival or recurrence free survival, respectively. Conclusions: We report the first evidence of prevalent FOLH1 expression within MCC-associated neo-vessels, in 60-77% of patients in a large MCC cohort. Given this data, and the need for alternatives to immune therapies it is appropriate to explore the safety and efficacy o f FOLH1-targeted brachytherapy for MCC.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Meier-Schiesser, B $u Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland
700    1_
$a Lachance, K $u Department of Dermatology, University of Washington, Seattle, Washington, USA
700    1_
$a Mahase, S S $u Department of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA
700    1_
$a Church, C D $u Department of Dermatology, University of Washington, Seattle, Washington, USA
700    1_
$a Niaz, M J $u Department of Urology, Weill Cornell Medicine, New York, New York, USA
700    1_
$a Liu, H $u Department of Urology, Weill Cornell Medicine, New York, New York, USA
700    1_
$a Navarro, V $u Department of Urology, Weill Cornell Medicine, New York, New York, USA
700    1_
$a Nikolopoulou, A $u Department of Radiology, Weill Cornell Medicine, New York, New York, USA
700    1_
$a Kazakov, D V $u Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic
700    1_
$a Contassot, E $u Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland
700    1_
$a Nguyen, D P $u Department of Urology, Weill Cornell Medicine, New York, New York, USA
700    1_
$a Sach, J $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic
700    1_
$a Hadravsky, L $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic
700    1_
$a Sheng, Y $u Shanghai Proton and Heavy Ion Center, Shanghai, China
700    1_
$a Tagawa, S T $u Department of Urology, Weill Cornell Medicine, New York, New York, USA $u Department of Medicine, Weill Cornell Medicine, New York, New York, USA
700    1_
$a Wu, X $u Shanghai Proton and Heavy Ion Center, Shanghai, China $u Innovative Cancer Institute, Miami, Florida, USA
700    1_
$a Lange, C S $u Department of Life Sciences, BioFort®, Guaynabo, Puerto Rico, USA $u Department of Radiation Oncology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA
700    1_
$a French, L E $u Department of Dermatology, Münich University Hospital, Münich, Germany
700    1_
$a Nghiem, P T $u Department of Dermatology, University of Washington, Seattle, Washington, USA
700    1_
$a Bander, N H $u Department of Urology, Weill Cornell Medicine, New York, New York, USA
773    0_
$w MED00208003 $t Skin health and disease $x 2690-442X $g Roč. 1, č. 1 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34541577 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133828 $b ABA008
999    __
$a ind $b bmc $g 1708412 $s 1145155
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 1 $c 1 $e 20201128 $i 2690-442X $m Skin health and disease $n Skin health dis. $x MED00208003
GRA    __
$a K24 CA139052 $p NCI NIH HHS $2 United States
GRA    __
$a P01 CA225517 $p NCI NIH HHS $2 United States
GRA    __
$a P30 CA015704 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Možnosti archivace